Publications - Page 51 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP)
An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension

Ryanto GRT, Ikeda K, Miyagawa K, Tu L, Guignabert C, Humbert M, Fujiyama T, Yanagisawa M, Hirata KI, Emoto N.

Nat Commun. 2021 Mar 19;12(1):1720. Doi: 10.1038/s41467-021-21961-3.
Hypertension pulmonaire (HTP)
Risk Stratification in Pulmonary Arterial Hypertension : Do Not Forget the Patient Perspective

Humbert M, Lau EMT

Am J Respir Crit Care Med. 2021 Mar 15;203(6):675-677. Doi: 10.1164/rccm.202012-4350ED.
Hypertension pulmonaire (HTP)
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Ghofrani HA, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, Wirtz H, Helmersen DS, Tsangaris I, Barberá JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, Šimková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Hoeper MM; NEW COLLABORATORS LIST.

Respir Med. 2021 Mar;178:106220. Doi: 10.1016/j.rmed.2020.106220.
Hypertension pulmonaire (HTP)
Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C.

Certain MC, Chaumais MC, Jaïs X, Savale L, Seferian A, Parent F, Georges M, Favrolt N, Bourdin A, Boissin C, Cottin V, Traclet J, Renard S, Noel V, Picard F, Girerd B, Ghigna MR, Perros F, Sitbon O, Bonniaud P, Humbert M, Montani D.

Chest. 2021 Mar;159(3):1197-1207. Doi: 10.1016/j.chest.2020.09.238.
Hypertension pulmonaire (HTP)
Reversible pulmonary hypertension associated with multivisceral Whipple’s disease

Camboulive A, Jutant EM, Savale L, Jaïs X, Sitbon O, Mussini C, Bénichou J, Lagier JC, Humbert M, Montani D.

Eur Respir J. 2021 Feb 25;57(2):2003132. Doi: 10.1183/13993003.03132-2020.
Hypertension pulmonaire (HTP)
Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance ?

Weatherald J, Boucly A, Savale L, Jaïs X, Montani D, Humbert M, Sitbon O.

Am J Respir Crit Care Med. 2021 Feb 15;203(4):524-525. Doi: 10.1164/rccm.202009-3664LE.
Hypertension pulmonaire (HTP)
Targeting transforming growth factor-β receptors in pulmonary hypertension

Guignabert C, Humbert M.

Eur Respir J. 2021 Feb 4;57(2):2002341. Doi: 10.1183/13993003.02341-2020.
Hypertension pulmonaire (HTP)
Pulmonary arterial hypertension in systemic sclerosis

Lechartier B, Humbert M.

Presse Med. 2021 Feb 3;50(1):104062. Doi: 10.1016/j.lpm.2021.104062.
Hypertension pulmonaire (HTP)
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis : Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease

Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, Ahmad K, Bertoletti L, Camara B, Gomez E, Launay D, Montani D, Mornex JF, Prévot G, Sanchez O, Schott AM, Subtil F, Traclet J, Turquier S, Zeghmar S, Habib G, Reynaud-Gaubert M, Humbert M, Cottin V.

Arthritis Rheumatol. 2021 Feb;73(2):295-304. Doi: 10.1002/art.41512.
Hypertension pulmonaire (HTP)
Kcnk3 Dysfunction Exaggerates The Development Of Pulmonary Hypertension Induced By Left Ventricular Pressure Overload

Lambert M, Mendes-Ferreira P, Ghigna MR, LeRibeuz H, Adão R, Boet A, Capuano V, Rucker-Martin C, Brás-Silva C, Quarck R, Domergue V, Vachiéry JL, Humbert M, Perros F, Montani D, Antigny F.

Cardiovasc Res. 2021 Jan 23: cvab016. Doi: 10.1093/cvr/cvab016.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension

Risk Stratification in Pulmonary Arterial Hypertension : Do Not Forget the Patient Perspective

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C.

Reversible pulmonary hypertension associated with multivisceral Whipple’s disease

Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance ?

Targeting transforming growth factor-β receptors in pulmonary hypertension

Pulmonary arterial hypertension in systemic sclerosis

Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis : Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease

Kcnk3 Dysfunction Exaggerates The Development Of Pulmonary Hypertension Induced By Left Ventricular Pressure Overload